Back to News

IMPAACT at CROI 2022

ShareShare

CROI 2022 graphic

 

 

The IMPAACT Network presented 17 abstracts from 12 studies (3 oral presentations, 14 poster presentations) at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022. The conference took place virtually from February 12-16.  

See below for full abstract listing. Presentations will be added as they become available.

View the recordings of presentations given to the ICAB in English, Spanish, Portuguese, and Thai here.

MONDAY, 14 FEBRUARY 

Protocol 

Title 

Authors 

Presentation Type & Time 

IMPAACT 2010 

Growth Of Infants with Perinatal Exposure to Maternal DTG vs EFV and TDF vs TAF 

Stranix-Chibanda L, Ziemba L, Brummel S, Johnston B, Mbengeranwa T, Cassim H, Theron G, Ngqawana Z, Wabwire D, McCarthy K, Chakhtoura N, Jean-Philippe P, Chinula L, Lockman S, for the IMPAACT 2010/VESTED study team and investigators 

Oral Presentation 

Maternal and Child Health: New Insights into Hepatitis, SARS- CoV-2 and HIV Session 

9:45 AM – 11:45 AM MT 

IMPAACT P1115 

Two Year Virologic Outcomes of Very Early ART for Infants in the IMPAACT P1115 Study 

Persaud D, Chadwick EG, Nelson BS, Tierney C, Cotton MF, Coletti A, Costello D, Nicodimus N, Stranix-Chibanda L, Kekitiinwa AR, Reding C, Majji S, Jean-Philippe P, Bryson Y, for the IMPAACT P1115 Team 

Oral Presentation 

Maternal and Child Health: New Insights into Hepatitis, SARS- CoV-2 and HIV Session 

9:45 AM – 11:45 AM MT 

IMPAACT 2010 

Pregnancy Hemoglobin A1c and glucose with DTG vs EFV, TDF vs TAF: IMPAACT 2010 

Chinula L, Goldberg E, Ziemba L, McCarthy K, Krotje C, Knowles K, Mathad J, Santos Cruz ML, Hoffman R, Jean-Philippe P, Chipato T, Wabwire D, Currier J, Lockman S, Chakhtoura N 

Poster Presentation  

Evolving Insights: MTCT Risk to Maternal Health Session  

2:00 PM – 3:30 PM MT 

NICHD P1081  Weight Gain with Raltegravir vs. Efavirenz During Pregnancy  Coutinho CM, Warshaw M, Duarte G, Stek A, Violari A, Hofer CB, Deville J, Ngocho JS, Pilotto J, Correa Jr MD, Fuller T, Chakhtoura N, Mirochnick M, João E 

Poster Presentation  

Evolving Insights: MTCT Risk to Maternal Health Session  

2:00 PM – 3:30 PM MT 

PROMISE P1084s 

Association of Maternal TDF-containing ART with Bone Mineral Content in Breastfed Infants 

Vhembo T, Baltrusaitis K, Tierney C, Owor M, Dadabhai S, Violari A, Theron G, Moodley D, Kahari-Mukwasi C, George K, Shepherd J, Siberry G, Fowler MG, and Stranix-Chibanda L, for the IMPAACT P1084s Study Team 

Poster Presentation 

New Perspectives on the Health of Children Exposed to HIV In Utero Session 

2:00 PM – 3:30 PM MT 

IMPAACT P1078 Maternal IPT In Pregnancy and Growth Faltering Among HIV-Exposed Uninfected Infants Cherkos AS, LaCourse S, Enquobahrie DA, Montepiedra G, Onyanog C, Mmbaga BT, Vhembo T, Masheto G, Theron G, Weinberg A, Gupta A, John-Stewart G

Poster Presentation 

New Perspectives on the Health of Children Exposed to HIV In Utero Session 

2:00 PM – 3:30 PM MT 

IMPAACT 2010 

HIV Drug Resistance in Women Randomized to DTG vs EFV or TDF vs TAF in Pregnancy 

Boyce C, Ziemba L, Brummel S, McCarthy K, Knowles K, Styrchak S,Browning R, Chakhtoura N, Moyo S, Vhembo T, Korutaro V, Pilotto JH, Chinula L, Lockman S, Frenkel LM 

Poster Presentation 

Impact of HIV Mutations on Fitness, Drug Resistance, and Treatment Response Session 

2:00 PM – 3:30 PM MT 

  

Tuesday, 15 February 

Protocol 

Title 

Authors 

Presentation Type & Time 

IMPAACT P1107 

HIV-1 Remission with CCR5Δ32Δ32 Haplo-Cord Transplant in a US Woman: IMPAACT P1107 

Hsu J, Van Besien K, Glesby M, Coletti A, Pahwa S, Warshaw M, Golner A, Bone F, Tobin N, Riches M, Mellors J, Browning R, Persaud D, Bryson Y, and the IMPAACT P1107 Team 

Oral Presentation  

HIV Reservoirs and Cure Strategies Session  

9:45 AM – 11:45 AM MT 

IMPAACT 2010 Risk-benefit Trade-off for Pregnancy and Infant Outcomes: DTG, EFV, TAF, and TDF  Brummel S, Ziemba L, Coletti A, Chinula L, Krotje C, Browning R, Chakhtoura N, João E, Raesi M, Ngocho J, Aurpibul L, Stranix-Chibanda L, Shapiro R, Stringer J, Lockman S 

Poster Presentation  

HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms Session 

2:00 PM – 3:30 PM MT

IMPAACT 2010

Adverse Outcomes in Subsequent Pregnancies in the IMPAACT 2010 Trial 

Fairlie L, Brummel S, Ziemba L, Coletti A, Chinula L, Shapiro R, Stringer J, Browning R, Chakhtoura N, Mmbaga BT, Mhembere T, Masheto G, Nagaddya B, Naidoo M, Lockman S 

Poster Presentation  

HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms 

2:00 PM – 3:30 PM MT 

PROMISE 1077BF/1077FF 

Impact of Maternal Hepatitis B Virus Co- infection on Pregnancy and Infant Outcomes in the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study 

Matovu FK, Tierney C, Chang A, Moodley D, Govender V, Vhembo T, Mohtashemi N, Ship H, Musoke P, Dula D, George K, Chakhtoura N, Peters MG, Fowler MG, Currier JS, Bhattacharya D 

Poster Presentation  

HIV, ART, and Pregnancy Outcomes: Epidemiology and Mechanisms 

2:00 PM – 3:30 PM MT 

IMPAACT P1115 

Is Routine PCP Prophylaxis Needed in Very Early-treated Infants with HIV? 

Nelson BS, Tierney C, Persaud D, Jao J, Cotton MF, Bryson Y, Bacon K, Costello D, Perlowski C, Santos Cruz ML, Kosgei J, Majji S, Yin D, Chadwick EG, for the IMPAACT P1115 Team 

Poster Presentation 

Early Treatment and HIV Reservoirs in Children Session 

2:00 PM – 3:30 PM MT 

IMPAACT 2032 

IMPAACT 2032: Remdesivir PK & Safety in Pregnant and Non-pregnant Women with COVID-19 

Brooks KM, Baltrusaitis K, Momper J, Greene E, Bone F, Bacon K, Humeniuk R, Yin DE, Chakhtoura N, Stek AM, Capparelli E, Mirochnick M, Clarke DF, Best B, on behalf of the IMPAACT 2032 Study Team 

Poster Presentation 

COVID-19 in Mothers and Their Children Session 

2:00 PM – 3:30 PM MT 

  

Wednesday, 16 February 

Protocol 

Title 

Authors 

Presentation Type & Time 

IMPAACT P1112 

Extended Safety and PK and Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants 

Cunningham CK, Capparelli EV, McFarland EJ, Muresan P, Perlowski C, Yin D, Moye J, Majji S, Purdue L, Harding PA, McDermott A, Mascola JR, Graham BS, for the IMPAACT P1112 team 

Poster Presentation  

PK, Safety, and Acceptability of New Agents for Children and Youth Session  

2:00 PM – 3:30 PM MT 

IMPAACT 2019 IMPAACT 2019: PK & Safety of Dispersible ABC/DTG/3TC in Children with HIV 6 to <14 kg  Brooks KM, Kiser JJ, Rani Y, Masheto GR, Patel F, Mustich I, Heckman B, Lojacono M, Yin DE, Majji S, Chandasana H, Rabie H, Flynn P, on behalf of the IMPAACT 2019 Team 

Poster Presentation  

PK, Safety, and Acceptability of New Agents for Children and Youth Session  

2:00 PM – 3:30 PM MT 

IMPAACT 2017 Safety and PK of Long-acting Cabotegravir and Rilpivirine in Adolescents Bolton Moore C, Capparelli E, Calabrese K, Best B, Ward S, McCoig C, Crauwel H, Agwu A, Samson P, Heckman B, Ford S, Adeyeye A, Moye J, Camacho-Gonzalez A, Gaur AH

Poster Presentation  

PK, Safety, and Acceptability of New Agents for Children and Youth Session  

2:00 PM – 3:30 PM MT

IMPAACT 2017

Adolescent and Parent Experiences with Long- acting Injectables in the MOCHA Study 

Lowenthal, E.D., Chapman J, Calabrese K, Milligan R, Agwu A, Camacho-Gonzalez A, Smith-Anderson C, Kneebone J, McCoig C, Harrington C.M., Van Solingen-Ristea R, Adeyeye A, Moye J, Bolton Moore C, Gaur A.H.

Poster Presentation  

PK, Safety, and Acceptability of New Agents for Children and Youth Session  

2:00 PM – 3:30 PM MT